EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Longitudinal Evaluation of Immunological Biomarkers in Previously Untreated/Minimally Treated Patients With Severe and Moderately Severe Haemophilia A During Exposure to Factor VIII: Results From the HEMFIL Study

Márcio Antônio Portugal Santana iD, Daniel Gonçalves Chaves iD, Renan Pedra Souza iD, Leticia Lemos Jardim iD, Luciana Werneck Zuccherato, Brendon Ayala Silva Santos, Mônica Hermida Cerqueira, Claudia Santos Lorenzato iD, Vivian Karla Brognoli Franco, Suely Meireles Rezende iD

Haemophilia · 2025

DOI: 10.1111/hae.70048 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Haemophilia, 2025. Verfasst von Márcio Antônio Portugal Santana und 9 weiteren Autor:innen. Beteiligte Einrichtung: Fundação Hemominas, Belo Horizonte, Minas Gerais, Brazil. Hauptthemen laut MEDLINE: Hemophilia A, Factor VIII, Biomarkers. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Haemophilia A (HA) is an inherited bleeding disorder due to Factor VIII (FVIII) deficiency. Treatment with FVIII can activate immune mechanisms, which may lead to inhibitor development.

Objectives

This study aimed to perform a longitudinal and exploratory analysis of immunological biomarkers during replacement with FVIII concentrate and after immune tolerance induction (ITI) in patients who developed a high‐responding inhibitor.

Methods

Biological samples and clinical data from severe and moderately severe persons with HA (PwHA; FVIII < 0.02 IU/mL) were obtained before any or after minimal exposure (≤5 days) to FVIII (T0), at inhibitor development (INB+), at 75 exposure days (ED) without inhibitor (INB−) (T1) and at end of ITI (T2). Biomarkers were assessed at T0, T1 and T2.

Results

One hundred patients were analysed, of whom 32 (86.5%) developed high‐responding inhibitor and underwent ITI. We found no difference in the plasma concentration of the 15 immunological biomarkers at T0 or at T1 versus T2 in INB+ compared with INB−. However, at T1, PwHA INB+ who failed ITI had higher median concentration of interleukin (IL)‐2 (3.50 vs. 0.85 pg/mL; q = 0.016), IL‐10 (3.46 vs. 0.74 pg/mL; q = 0.035), tumour necrosis factor (TNF) (11.18 vs. 0.93 pg/mL; q = 0.016), interferon‐gamma (INF‐γ) (98.57 vs. 3.57 pg/mL; q = 0.035) and CCL5 (5245.11 vs. 3107.86 pg/mL; p = 0.037) compared with those who achieved complete response, respectively.

Conclusions

Patients who failed ITI had higher concentration of IL‐2, IL‐10, TNF, INF‐γ and CCL5 in comparison with complete responders, suggesting that these biomarkers could be potential predictors of ITI outcome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AFactor VIIIBiomarkersHumansMaleLongitudinal StudiesAdultMiddle AgedYoung AdultAdolescentFemaleSeverity of Illness IndexChildImmune Tolerance

Stichwörter der Autor:innen

Factor VIIIhaemophilia Aimmunological biomarkersinhibitorrisk factor

Substanzen

Factor VIIIBiomarkers

Autor:innen und Institutionen

  • Fundação Hemominas, Belo Horizonte, Minas Gerais, Brazil.
  • Faculty of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
  • Instituto of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
  • Instituto Renè Rachou (Fiocruz Minas), Belo Horizonte, Minas Gerais, Brazil.
  • Faculdade de Ciências Médicas de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
  • Instituto de Hematologia Arthur de Siqueira Calvalcanti (HEMORIO), Rio de Janeiro, Brazil.

ORCID-Profile: Márcio Antônio Portugal Santana, Daniel Gonçalves Chaves, Renan Pedra Souza, Leticia Lemos Jardim, Claudia Santos Lorenzato, Suely Meireles Rezende

Zitieren

APA

Antônio Portugal Santana, M., Gonçalves Chaves, D., Souza, R. P., Jardim, L. L., Zuccherato, L. W., Santos, B. A. S., Cerqueira, M. H., Lorenzato, C. S., Franco, V. K. B., & Rezende, S. M. (2025). Longitudinal Evaluation of Immunological Biomarkers in Previously Untreated/Minimally Treated Patients With Severe and Moderately Severe Haemophilia A During Exposure to Factor VIII: Results From the HEMFIL Study. Haemophilia. https://doi.org/10.1111/hae.70048

Vancouver

Antônio Portugal Santana M, Gonçalves Chaves D, Souza RP, Jardim LL, Zuccherato LW, Santos BAS, et al. Longitudinal Evaluation of Immunological Biomarkers in Previously Untreated/Minimally Treated Patients With Severe and Moderately Severe Haemophilia A During Exposure to Factor VIII: Results From the HEMFIL Study. Haemophilia. 2025. doi:10.1111/hae.70048

BibTeX
@article{AntnioPortugalSantana2025,
  author = {Antônio Portugal Santana, Márcio and Gonçalves Chaves, Daniel and Souza, Renan Pedra and Jardim, Leticia Lemos and Zuccherato, Luciana Werneck and Santos, Brendon Ayala Silva and Cerqueira, Mônica Hermida and Lorenzato, Claudia Santos and Franco, Vivian Karla Brognoli and Rezende, Suely Meireles},
  title = {Longitudinal Evaluation of Immunological Biomarkers in Previously Untreated/Minimally Treated Patients With Severe and Moderately Severe Haemophilia A During Exposure to Factor VIII: Results From the HEMFIL Study},
  journal = {Haemophilia},
  year = {2025},
  doi = {10.1111/hae.70048}
}
Kostenlos starten →